<DOC>
	<DOC>NCT00532168</DOC>
	<brief_summary>There are few randomized clinical trials in advanced HIV patients. This is a multicenter, randomized, open clinical trial, comparing three parallel groups, to compare the immunological reconstitution and the virological efficacy and safety of three different combinations of antiretroviral therapy given once a day (QD): tenofovir plus emtricitabine plus either efavirenz, lopinavir-ritonavir or atazanavir-ritonavir during 96 weeks in advanced antiretroviral na√Øve HIV-1 infected patients with less than 100 CD4+ T-cells/mm3. Primary endpoint is the median increase in CD4+ T-cell count at 48 weeks after starting HAART.</brief_summary>
	<brief_title>Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Chronic HIV1 infection Age 18 or more Antiretroviralnaive Baseline CD4+ count &lt;100 cels/mcL. No mutations of drug resistance at baseline (M184V/I, K65R, resistance to efavirenz or 2 or more PRAMs (L33I/F/V, V82A/F/L/T, I84V, L90M) Written informed consent Hypersensibility to study drugs. Pregnancy or breastfeeding Active OI requiring admission Active lymphoma or malignancy (Kaposi sarcoma included) Cl creatinine below 30 ml/min. Liver failure Treatment with nephrotoxic drugs, immunomodulators, interleukine2, systemic steroids or investigational products.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>advanced HIV-infected patients</keyword>
	<keyword>late presenters</keyword>
	<keyword>antiretroviral therapy</keyword>
	<keyword>immune reconstitution</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>